PRKAA1 and hepatocellular carcinoma: The mechanism of MET action in DM patients on HCC prevention and treatment is supposed to be related to the AMPK pathway, whereas MET activates AMPK expression by increasing the cellular energy stress, which triggers insulin/IGF-1 signaling inhibition that is involved in the control of cancer glycolysis and carcinogenesis [23].